Drug firm Bajaj Healthcare on Tuesday announced the launch of its antiviral Favipiravir tablets under the brand name 'Favijaj' used for the treatment of mild to moderate Covid-19 infections in the country. The company has received approval from India's drug regulator DCGI to manufacture and market the tablets, Bajaj Healthcare said in a BSE filing."We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure and offer patients much-needed and timely therapy options," Bajaj Healthcare Joint MD Anil Jain said.The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team, Bajaj Healthcare said.
